| Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? S Gill, CL Loprinzi, DJ Sargent, SD Thomé, SR Alberts, DG Haller, ... Journal of clinical oncology 22 (10), 1797-1806, 2004 | 1322 | 2004 |
| Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer E Van Cutsem, WL Vervenne, J Bennouna, Y Humblet, S Gill, ... Journal of clinical oncology 27 (13), 2231-2237, 2009 | 792 | 2009 |
| Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial SR Alberts, DJ Sargent, S Nair, MR Mahoney, M Mooney, SN Thibodeau, ... Jama 307 (13), 1383-1393, 2012 | 590 | 2012 |
| A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors AM Scott, FT Lee, N Tebbutt, R Herbertson, SS Gill, Z Liu, E Skrinos, ... Proceedings of the National Academy of Sciences 104 (10), 4071-4076, 2007 | 305 | 2007 |
| Role of cyclooxygenase-2 in colorectal cancer FA Sinicrope, S Gill Cancer and Metastasis Reviews 23, 63-75, 2004 | 297 | 2004 |
| PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received … S Gill, YJ Ko, C Cripps, A Beaudoin, S Dhesy-Thind, M Zulfiqar, ... J Clin Oncol 34 (32), 3914-3920, 2016 | 279 | 2016 |
| The colon health and life-long exercise change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group KS Courneya, CM Booth, S Gill, P O’Brien, J Vardy, CM Friedenreich, ... Current oncology 15 (6), 271, 2008 | 202 | 2008 |
| The Chennai Declaration: a roadmap to tackle the challenge of antimicrobial resistance A Ghafur, D Mathai, A Muruganathan, JA Jayalal, R Kant, D Chaudhary, ... Indian Journal of Cancer 50 (1), 71-73, 2013 | 181 | 2013 |
| Adjuvant chemotherapy use and outcomes of patients with high‐risk versus low‐risk stage II colon cancer A Kumar, HF Kennecke, DJ Renouf, HJ Lim, S Gill, R Woods, C Speers, ... Cancer 121 (4), 527-534, 2015 | 155 | 2015 |
| Asian ethnicity–related differences in gastric cancer presentation and outcome among patients treated at a Canadian Cancer Center S Gill, A Shah, N Le, EF Cook, EM Yoshida Journal of clinical oncology 21 (11), 2070-2076, 2003 | 153 | 2003 |
| Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III … SR Alberts, DJ Sargent, TC Smyrk, AF Shields, E Chan, RM Goldberg, ... Journal of Clinical Oncology 28 (18_suppl), CRA3507-CRA3507, 2010 | 147 | 2010 |
| Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial DJ Jonker, L Nott, T Yoshino, S Gill, J Shapiro, A Ohtsu, J Zalcberg, ... The lancet Gastroenterology & hepatology 3 (4), 263-270, 2018 | 145 | 2018 |
| NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma MR Jones, LM Williamson, JT Topham, MKC Lee, A Goytain, J Ho, ... Clinical Cancer Research 25 (15), 4674-4681, 2019 | 143 | 2019 |
| Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis GK Gresham, GA Wells, S Gill, C Cameron, DJ Jonker BMC cancer 14, 1-13, 2014 | 139 | 2014 |
| Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma HC Toh, PJ Chen, BI Carr, JJ Knox, S Gill, P Ansell, EM McKeegan, ... Cancer 119 (2), 380-387, 2013 | 134 | 2013 |
| Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review K Saad El Din, JM Loree, EC Sayre, S Gill, CJ Brown, H Dau, MA De Vera BMC cancer 20, 1-14, 2020 | 125 | 2020 |
| Adjuvant therapy for stage II colon cancer: ASCO guideline update NN Baxter, EB Kennedy, E Bergsland, J Berlin, TJ George, S Gill, PJ Gold, ... Journal of Clinical Oncology 40 (8), 892-910, 2022 | 124 | 2022 |
| Obstacles to residents' conducting research and predictors of publication S Gill, A Levin, O Djurdjev, EM Yoshida Academic Medicine 76 (5), 477, 2001 | 120 | 2001 |
| PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study SR Alberts, NR Foster, RF Morton, J Kugler, P Schaefer, M Wiesenfeld, ... Annals of Oncology 16 (10), 1654-1661, 2005 | 119 | 2005 |
| Colorectal cancer chemotherapy S Gill, RR Thomas, RM Goldberg Alimentary pharmacology & therapeutics 18 (7), 683-692, 2003 | 114 | 2003 |
